Related Experiment Video
Updated: Mar 26, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Relation of Plasma Fibrinogen Level With the Presence, Severity, and Complexity of Coronary Artery Disease
Mehmet Mustafa Tabakcı1, Fethullah Gerin2, Murat Sunbul3
11 Cardiology Department, Kartal Koşuyolu Cardiovascular Research and Training Hospital, Istanbul, Turkey.
Insights
Plasma fibrinogen, a marker of inflammation, is strongly linked to the severity and complexity of coronary artery disease (CAD). Higher fibrinogen levels predict more complex coronary artery disease in patients with stable angina.
Area of Science:
- Cardiology
- Biomarkers
- Inflammation
Background:
- The relationship between plasma fibrinogen levels and the extent, severity, and complexity of coronary artery disease (CAD) in patients with stable angina pectoris (SAP) remains under-investigated.
- Assessing this relationship is crucial for understanding disease progression and potential therapeutic targets.
Purpose of the Study:
- To evaluate the association between plasma fibrinogen levels and coronary complexity, severity, and extent.
- To determine if plasma fibrinogen can serve as a predictor for high SYNTAX scores (SS) in patients with stable angina.
Main Methods:
- 134 consecutive patients with SAP undergoing coronary angiography were enrolled.
- Baseline plasma fibrinogen levels were measured, and the SYNTAX score (SS) was calculated for each patient.
- Patients were stratified into three groups based on SS tertiles: control (SS=0), intermediate (SS<22), and high (SS≥22).
Main Results:
- Plasma fibrinogen levels showed a significant stepwise increase from the control group to the high SS group.
- A strong positive correlation was observed between plasma fibrinogen levels and SS (r=0.535, P<.001).
- Plasma fibrinogen was identified as an independent predictor of high SS (OR 1.01, P<.001), with a threshold of 411 mg/dL demonstrating 75% sensitivity and 64% specificity for predicting high SS.
Conclusions:
- Plasma fibrinogen is a readily measurable systemic inflammatory marker.
- Plasma fibrinogen levels are independently associated with coronary artery disease severity and complexity in patients with stable angina.
- These findings suggest plasma fibrinogen's potential utility in risk stratification for patients with CAD.
Background:
Relation of plasma fibrinogen levels with extent, severity, and complexity of coronary artery disease (CAD) in patients with stable angina pectoris (SAP) has not been adequately investigated. The aim of this study was to evaluate whether plasma fibrinogen level is associated with coronary complexity, severity, and extent assessed by SYNTAX (Synergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery) score (SS).
Methods:
We enrolled 134 consecutive patients with SAP who underwent coronary angiography. Baseline serum fibrinogen levels were measured, and SS was calculated from the study population. The patients were classified into 3 groups by tertiles of SS (SS, control group = 0; intermediate group < 22; and high group ≥ 22).
Results:
Plasma fibrinogen levels demonstrated a stepwise increase from control group to high SS group. There was a strong correlation between fibrinogen and the SS ( r = .535, P < .001). Area under the receivers operating characteristic curve of fibrinogen was 0.72 (95% confidence interval [CI] 0.61-0.82; < .001) for predicting a high SS. Fibrinogen value higher than 411 mg/dL has a sensitivity of 75% and a specificity of 64% in prediction of high SS. In multivariate analyses, plasma fibrinogen was observed to be an independent predictor for high SS in patients with stable CAD (odds ratio [OR] 1.01; 95% CI, 1.01-1.02; P < .001).
Conclusion:
Plasma fibrinogen is a readily measurable systemic inflammatory marker and is independently associated coronary severity and complexity in patients with CAD.
More Related Videos
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coronary Artery Disease IV: Preventive Measures
Clot Retraction and Fibrinolysis
Coronary Artery Disease III: Clinical Manifestations

